Glaukos (NYSE: GKOS) Stock Surges on Strong Q2 Earnings and Upbeat Outlook

• Glaukos (NYSE: GKOS) received an increased price target of $195.00 from H.C. Wainwright, signaling a potential 14.26% upside.
• The medical technology company reported an adjusted loss of only $0.14 per share, significantly beating analyst estimates, with revenues soaring 50% to a record $185.60 million.
• Following robust performance, Glaukos raised its 2026 sales guidance to between $680.00 million and $700.00 million, leading to a 9.8% jump in shares after-market.

Glaukos (NYSE: GKOS) is a leading medical technology company specializing in the development and sale of innovative ophthalmic therapies for eye diseases, including glaucoma treatment and corneal disorders. Analyst firm H.C. Wainwright recently increased its stock price target on Glaukos to $195.00 from $168.00. This analyst price target represents an estimate of a stock's future value, suggesting a potential 14.26% upside from its price at the time.

This optimistic view is strongly supported by the company's robust financial results. For its second quarter of 2026, Glaukos reported an adjusted loss of only $0.14 per share. This impressive Q2 earnings performance was significantly better than the $0.28 loss that analysts had predicted, resulting in a positive earnings surprise of 50%.

The company's revenues also showed impressive revenue growth, increasing by 50% from the previous year to reach a record $185.60 million. As highlighted by Business Wire, this surge was largely due to the successful product adoption of its iDose TR product. This helped drive U.S. Glaucoma revenues up by 64% to a new high of $118.50 million.

Following these strong results, Glaukos updated its financial forecast for the rest of the year. The company raised its 2026 sales guidance to a new range of $680.00 million to $700.00 million. This is a notable increase from its previous projection of $620.00 million to $635.00 million, clearly showing confidence in its future performance and market position.

The market reacted exceptionally well to the company's outstanding stock performance. According to Zacks, Glaukos shares increased by 9.8% in after-market trading following the news. So far this year, the stock has gained an impressive 43.1%, performing much better than its industry, which has declined by 11.7%, and the broader S&P 500 Index.